Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-03-24

AUTHORS

Michael Cecchini, Mario Sznol, Stuart Seropian

ABSTRACT

Metastatic melanoma is frequently treated with immune activating therapy, which poses a theoretical risk of inducing graft versus host disease (GVHD) in those who have received allogeneic stem cell transplantation. The literature reporting the safety of immunotherapy in post transplant patients is limited. We report two patients with metastatic melanoma who received treatment with immunotherapy after allogeneic stem cell transplantation that did not result in GVHD. More... »

PAGES

10

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40425-015-0054-4

DOI

http://dx.doi.org/10.1186/s40425-015-0054-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1001455744

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25806109


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Medical Oncology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital Yale University School of Medicine, New Haven, USA", 
          "id": "http://www.grid.ac/institutes/grid.433818.5", 
          "name": [
            "Division of Medical Oncology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital Yale University School of Medicine, New Haven, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cecchini", 
        "givenName": "Michael", 
        "id": "sg:person.01113404226.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113404226.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Medical Oncology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital Yale University School of Medicine, New Haven, USA", 
          "id": "http://www.grid.ac/institutes/grid.433818.5", 
          "name": [
            "Division of Medical Oncology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital Yale University School of Medicine, New Haven, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sznol", 
        "givenName": "Mario", 
        "id": "sg:person.0706626451.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Medical Oncology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital Yale University School of Medicine, New Haven, USA", 
          "id": "http://www.grid.ac/institutes/grid.433818.5", 
          "name": [
            "Division of Medical Oncology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital Yale University School of Medicine, New Haven, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Seropian", 
        "givenName": "Stuart", 
        "id": "sg:person.01316207754.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316207754.43"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrclinonc.2013.153", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042806557", 
          "https://doi.org/10.1038/nrclinonc.2013.153"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-03-24", 
    "datePublishedReg": "2015-03-24", 
    "description": "Metastatic melanoma is frequently treated with immune activating therapy, which poses a theoretical risk of inducing graft versus host disease (GVHD) in those who have received allogeneic stem cell transplantation. The literature reporting the safety of immunotherapy in post transplant patients is limited. We report two patients with metastatic melanoma who received treatment with immunotherapy after allogeneic stem cell transplantation that did not result in GVHD.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s40425-015-0054-4", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1049249", 
        "issn": [
          "2051-1426"
        ], 
        "name": "Journal for ImmunoTherapy of Cancer", 
        "publisher": "BMJ", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "3"
      }
    ], 
    "keywords": [
      "allogeneic stem cell transplantation", 
      "stem cell transplantation", 
      "metastatic melanoma", 
      "cell transplantation", 
      "allogeneic bone marrow transplant", 
      "safety of immunotherapy", 
      "post-transplant patients", 
      "bone marrow transplant", 
      "host disease", 
      "transplant patients", 
      "immune therapy", 
      "marrow transplant", 
      "theoretical risk", 
      "melanoma", 
      "immunotherapy", 
      "transplantation", 
      "patients", 
      "therapy", 
      "GVHD", 
      "transplant", 
      "graft", 
      "disease", 
      "treatment", 
      "risk", 
      "safety", 
      "literature"
    ], 
    "name": "Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant", 
    "pagination": "10", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1001455744"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40425-015-0054-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25806109"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40425-015-0054-4", 
      "https://app.dimensions.ai/details/publication/pub.1001455744"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_670.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s40425-015-0054-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-015-0054-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-015-0054-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-015-0054-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-015-0054-4'


 

This table displays all metadata directly associated to this object as RDF triples.

104 TRIPLES      21 PREDICATES      52 URIs      43 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40425-015-0054-4 schema:about anzsrc-for:11
2 anzsrc-for:1107
3 schema:author Nc27cda58ad1e4d33803ce2d6c8fb28ec
4 schema:citation sg:pub.10.1038/nrclinonc.2013.153
5 schema:datePublished 2015-03-24
6 schema:datePublishedReg 2015-03-24
7 schema:description Metastatic melanoma is frequently treated with immune activating therapy, which poses a theoretical risk of inducing graft versus host disease (GVHD) in those who have received allogeneic stem cell transplantation. The literature reporting the safety of immunotherapy in post transplant patients is limited. We report two patients with metastatic melanoma who received treatment with immunotherapy after allogeneic stem cell transplantation that did not result in GVHD.
8 schema:genre article
9 schema:isAccessibleForFree true
10 schema:isPartOf N7eb0d5b574f84560ac11506281c5e23a
11 Nc56775f37b424cf089a7724d6d0424bb
12 sg:journal.1049249
13 schema:keywords GVHD
14 allogeneic bone marrow transplant
15 allogeneic stem cell transplantation
16 bone marrow transplant
17 cell transplantation
18 disease
19 graft
20 host disease
21 immune therapy
22 immunotherapy
23 literature
24 marrow transplant
25 melanoma
26 metastatic melanoma
27 patients
28 post-transplant patients
29 risk
30 safety
31 safety of immunotherapy
32 stem cell transplantation
33 theoretical risk
34 therapy
35 transplant
36 transplant patients
37 transplantation
38 treatment
39 schema:name Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant
40 schema:pagination 10
41 schema:productId N2632e1ea915a4fdd87ad143b76cffbf4
42 N569064dea19f4855b882232eb3d844e2
43 Nf303333c14354b82aadc28a7fdf2047e
44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001455744
45 https://doi.org/10.1186/s40425-015-0054-4
46 schema:sdDatePublished 2022-09-02T15:59
47 schema:sdLicense https://scigraph.springernature.com/explorer/license/
48 schema:sdPublisher N33cedea16b954eab811c20e1229b84da
49 schema:url https://doi.org/10.1186/s40425-015-0054-4
50 sgo:license sg:explorer/license/
51 sgo:sdDataset articles
52 rdf:type schema:ScholarlyArticle
53 N1acfa43416ed4c0eb1a519ecbdfa9ecc rdf:first sg:person.0706626451.72
54 rdf:rest N3c6f5f4b866d4c9088faed465c2bf3f6
55 N2632e1ea915a4fdd87ad143b76cffbf4 schema:name pubmed_id
56 schema:value 25806109
57 rdf:type schema:PropertyValue
58 N33cedea16b954eab811c20e1229b84da schema:name Springer Nature - SN SciGraph project
59 rdf:type schema:Organization
60 N3c6f5f4b866d4c9088faed465c2bf3f6 rdf:first sg:person.01316207754.43
61 rdf:rest rdf:nil
62 N569064dea19f4855b882232eb3d844e2 schema:name doi
63 schema:value 10.1186/s40425-015-0054-4
64 rdf:type schema:PropertyValue
65 N7eb0d5b574f84560ac11506281c5e23a schema:issueNumber 1
66 rdf:type schema:PublicationIssue
67 Nc27cda58ad1e4d33803ce2d6c8fb28ec rdf:first sg:person.01113404226.86
68 rdf:rest N1acfa43416ed4c0eb1a519ecbdfa9ecc
69 Nc56775f37b424cf089a7724d6d0424bb schema:volumeNumber 3
70 rdf:type schema:PublicationVolume
71 Nf303333c14354b82aadc28a7fdf2047e schema:name dimensions_id
72 schema:value pub.1001455744
73 rdf:type schema:PropertyValue
74 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
75 schema:name Medical and Health Sciences
76 rdf:type schema:DefinedTerm
77 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
78 schema:name Immunology
79 rdf:type schema:DefinedTerm
80 sg:journal.1049249 schema:issn 2051-1426
81 schema:name Journal for ImmunoTherapy of Cancer
82 schema:publisher BMJ
83 rdf:type schema:Periodical
84 sg:person.01113404226.86 schema:affiliation grid-institutes:grid.433818.5
85 schema:familyName Cecchini
86 schema:givenName Michael
87 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113404226.86
88 rdf:type schema:Person
89 sg:person.01316207754.43 schema:affiliation grid-institutes:grid.433818.5
90 schema:familyName Seropian
91 schema:givenName Stuart
92 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316207754.43
93 rdf:type schema:Person
94 sg:person.0706626451.72 schema:affiliation grid-institutes:grid.433818.5
95 schema:familyName Sznol
96 schema:givenName Mario
97 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72
98 rdf:type schema:Person
99 sg:pub.10.1038/nrclinonc.2013.153 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042806557
100 https://doi.org/10.1038/nrclinonc.2013.153
101 rdf:type schema:CreativeWork
102 grid-institutes:grid.433818.5 schema:alternateName Division of Medical Oncology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital Yale University School of Medicine, New Haven, USA
103 schema:name Division of Medical Oncology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital Yale University School of Medicine, New Haven, USA
104 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...